. Author manuscript; available in PMC: 2016 Mar 15.

Published in final edited form as: Toxicol Appl Pharmacol. 2015 Jan 28;283(3):168–177. doi: 10.1016/j.taap.2015.01.015

Table 2. Bile and Serum Bile Acid Values in Patients.

Bile acid levels were measured in serum and bile of patients with and without cholestatic liver injury via UPLC/QTOFMS (as described in methods). Patient groups were defined by elevations in ALT and ALP.

	Bile		Serum
Bile Acid	UI Patient (μM)	CLI Patient (μM)	UI Patient (μM)	CLI Patient (μM)
LCA	<10	<10	<0.1	<0.1
UDCA	67 ± 20	71 ± 20	<0.1	<0.1
CDCA	<10	<10	0.9 ± 0.3	0.4 ± 0.1
DCA	116 ± 100	25 ± 16	1.0 ± 0.4	0.1 ± 0.1^*^#
CA	<10	<10	<0.1	<0.1
TCA	2,403 ± 223	2,460 ± 295	0.4 ± 0.1	11.7 ± 4.2^*
GCDC	4,325 ± 661	2,756 ± 339	2.8 ± 0.4	22.1 ± 5.3^*
TCDC	1,067 ± 217	1,058 ± 191	0.4 ± 0.1	6.8 ± 1.6^*
GCA	3,030 ± 600	1,530 ± 269	0.4 ± 0.1	7.6 ± 1.9^*
GDCA	3,643 ± 742	1,152 ± 355^*	0.8 ± 0.3	3.8 ± 1.3^*
TDCA	712 ± 202	607 ± 320	0.3 ± 0.1	1.2 ± 0.3^*

P<0.05 (versus UI patients).

some samples not detectable within standard curve.

LCA, lithocholic acid; UDCA, ursodeoxycholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; CA, cholic acid; TCA, taurocholic acid; GCDC, glycochenodeoxycholic acid; TCDC, taurochenodeoxycholic acid; GCA, glycocholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid.